CNS Pharmaceuticals (CNSP) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on CNS Pharmaceuticals (CNSP) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.00 of bullish evidence against -0.48 bearish.

CNS Pharmaceuticals last closed at $5.35, +0.00% on the session.

Against the IVW growth benchmark the position is -0.80% over the forecast window.

The read is built from 15 underlying insights — 0 bullish and 15 bearish.

Agreement across those insights is 100%.

20 graded predictions for CNSP so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks CNS Pharmaceuticals in the 5th percentile on return on equity, where 100 is best.

CNS Pharmaceuticals is classified under Health Care / Pharmaceuticals, with a market capitalisation of $7.82M.

StockMap tracks CNS Pharmaceuticals as the 132nd largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite CNS Pharmaceuticals ranks 105th of 151 in the group, against a group median of -0.08.